Real-world, 52-week Prospective Study to Capture the Reasons for Switch to Triple Combination Therapy, Assess the Clinical and Patient Reported Outcomes in Adults With Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD) Treated With Trixeo Aerosphere™ in Routine Care Settings in Greece
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
—
Status
Completed
Study type
Observational
Enrollment
212actual
Sites
15
Country
Greece
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-07-21 | actual | When the study began enrolling |
| Primary completion | 2025-03-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2025-03-28 | actual | The whole study's end, after follow-up |
| First posted | 2023-06-22 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-31 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pulmonary Disease, Chronic Obstructive (COPD)
Intervention
- Combination product: Budesonide Glycopyrronium bromide Formoterol fumarate pressurized Metered Dose Inhaler
Primary outcomes
what the primary-completion date above is the date OFChange from baseline in the CAT total and item scores at 12 weeks post index
measured At 12 weeks after treatment initiation
Percentage of patients achieving a ≥ 2-point reduction from baseline in CAT total score at 12 weeks post index
measured At 12 weeks after treatment initiation
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed